The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.
 
Solange Peters
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Merck Serono; MSD; Novartis; Pfizer; Regeneron; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Dirk De Ruysscher
No Relationships to Disclose
 
Urania Dafni
No Relationships to Disclose
 
Enriqueta Felip
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer; Roche
 
Matthias Guckenberger
No Relationships to Disclose
 
Johan F. Vansteenkiste
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst)
Research Funding - MSD (Inst)
 
Rudolf M. Huber
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Guardant Health; Lilly; Merck; Mologen; Novartis; Pfizer; Roche; Takeda
 
Ernest Nadal-Alforja
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Research Funding - Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Pfizer; Roche
 
Antonio Irigoyen
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Annemarie Becker
No Relationships to Disclose
 
Anne-Christine Piguet
No Relationships to Disclose
 
Marie Kassapian
No Relationships to Disclose
 
Adriana Gasca-Ruchti
No Relationships to Disclose
 
Alex Martinez Marti
No Relationships to Disclose
 
Nicolaus Andratschke
No Relationships to Disclose
 
Maarten Lambrecht
Employment - Ablynx (I)
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Roche
 
Claus Belka
Stock and Other Ownership Interests - Gilead Sciences; Novo Nordisk
Honoraria - Amgen; Merck; Roche
Consulting or Advisory Role - Amgen; Elekta; Merck
Research Funding - Elekta; Merck
Travel, Accommodations, Expenses - Amgen; Elekta; Merck; Roche
 
Heidi Roschitzki-Voser
No Relationships to Disclose
 
Rolf A. Stahel
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Speakers' Bureau - Astellas Pharma; Boehringer Ingelheim; Merck Sharp & Dohme